Nuclear Medicine and Biology
Volume 34, Issue 7 , Pages 729-732 , October 2007

Barriers to achieving commercial success for diagnostic and therapeutic radiopharmaceuticals

Received 26 March 2007 ,Accepted 8 April 2007.

References 

  1. Goldenberg DM, DeLand F, Kim E, Bennett S, Primus FJ, von Nagell JR, et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med. 1978;298:1384–1388
  2. Goldenberg DM. Radioimmunotherapy. In:  Freeman LM editors. Nuclear medicine annual 2001. Philadelphia: Lippincott Williams & Wilkins; 2001;p. 167–206
  3. Moore GA. Crossing the chasm. New York: HarperCollins; 2002;
  4. Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol. 2006;24:2793–2799
  5. Kalen JD, Hirsch JI, Kurdziel KA, Eckelman WC, Kiesewetter DO. Automated synthesis of [18F] analogue of paclitaxel (PAC): [18F]paclitaxel (FPAC). Appl Radiat Isot. 2007;65:696–700
  6. Smith-Jones PM, Solit DB, Afroze F, Rosen N, Larson SM. Early tumor response to Hsp90 therapy using HER2 PET: comparison with [18F]-FDG PET. J Nucl Med. 2006;47:793–796
  7. Ozdemir V, Willians-Jones B, Glatt SJ, Tsuang MT, Lohr JB, Reist C. Shifting the emphasis from pharmacogenomics to theragnostics. Nat Biotechnol. 2006;24:942–946

☆ After bench to bedside: impact on clinical outcome (February 25, 2007).

PII: S0969-8051(07)00100-X

doi: 10.1016/j.nucmedbio.2007.04.004

Nuclear Medicine and Biology
Volume 34, Issue 7 , Pages 729-732 , October 2007

Article Tools

* Image Usage & Resolution